Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 févr. 2017 07h30 HE | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC

Further Development of CD101 Topical for VVC to be discontinued CD101 IV development program in candidemia and invasive candidiasis (including Phase 2 STRIVE trial) continuing and remains on track ...
10 nov. 2016 16h10 HE | Source: Cidara Therapeutics, Inc.

Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results

SAN DIEGO, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
11 août 2016 16h12 HE | Source: Cidara Therapeutics, Inc.

Cidara Reports Second Quarter 2016 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other...
11 août 2015 16h13 HE | Source: Cidara Therapeutics, Inc.

Cidara Reports Second Quarter 2015 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections,...
05 août 2015 07h30 HE | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics to Present at the Wedbush PacGrow 2015 Healthcare Conference

SAN DIEGO, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections,...